Qiagen NV (NYSE:QGEN) is drawing renewed investor attention after reports that several private equity firms are evaluating a potential takeover of the molecular diagnostics company.
The stock surged 10.5% in the previous session on the takeover speculation, according to Benzinga Pro.
Private Equity Firms Circle Qiagen Bloomberg reported Thursday that EQT AB (OTC:EQBBF), Advent and KKR & Co.
Inc.
(NYSE:KKR) are among the firms studying a possible bid for Qiagen as the company continues a strategic review that could lead to a sale.
